Andria Louis
Optometrist · Gretna, NENPI 1225173669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 29.8% of the total. 2025 is the largest year on record at $970, more than ten times the $93 reported in 2020. Among optometrist clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$912
- AbbVie$858
- Amgen$258
- Alcon$232
- Biotissue Holdings Inc.$137
- Tarsus Pharmaceuticals, Inc.$130
- plus $531 from 15 others
What the payments were for
- Food & beverage$3,04199%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 29 | $912 |
| AbbVie(2 entities) | 48 | $858 |
| Amgen | 8 | $258 |
| Alcon | 6 | $232 |
| Biotissue Holdings Inc. | 3 | $137 |
| Tarsus Pharmaceuticals, Inc. | 5 | $130 |
| Rxsight Inc | 2 | $63 |
| Novartis | 4 | $57 |
| Aerie Pharmaceuticals, Inc. | 4 | $56 |
| Sun Pharmaceutical Industries Inc. | 3 | $49 |
| Harrow Eye, LLC | 2 | $45 |
| Coherus Oncology, Inc. | 2 | $44 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $41 |
| Dompe US, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $34 |
| Thea Pharma Inc. | 1 | $22 |
| Spark Therapeutics, Inc. | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Glaukos Corporation | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$250
- Voyager DSLT$130
- Hydrus Microstent$130
- XIIDRA$125
- LUMIGAN$120
- DURYSTA$120
- XEN GLAUCOMA TREATMENT SYSTEM$120
- VYZULTA$101
- TEPEZZA$100
How this compares
$3,058 in reported general payments places this provider in the 90th percentile of 383 optometrist providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 13 | $25,592 |
| CombiganBrimonidine Tartrate/Timolol | 50 | $21,804 |
| VyzultaLatanoprostene Bunod | 24 | $21,272 |
| LumiganBimatoprost | 37 | $19,304 |
| RestasisCyclosporine | 16 | $16,271 |
| CequaCyclosporine | 12 | $10,520 |
| Lotemax SmLoteprednol Etabonate | 40 | $10,096 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 42 | $9,919 |
| MieboPerfluorohexyloctane/Pf | 12 | $9,515 |
| Travoprost | 22 | $4,445 |
| Timolol MaleateTimolol Maleate/Pf | 12 | $2,832 |
| Brimonidine Tartrate | 61 | $2,436 |
| Timolol Maleate | 115 | $2,168 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 18 | $2,088 |
| Latanoprost | 317 | $2,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Restasis | $858 | $57,379103 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $912 | $30,78836 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $130 | $25,59213 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $49 | $10,52012 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $41 | $10,09640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 383 optometrist providers in Nebraska.
Other optometrist in Gretna
- Cheryl ChapmanGretna$13K
- Christopher WolfeOmaha$154K
- Brian BrightmanLincoln$16K
- Jeffrey KleinNorfolk$12K
- Mark ToelleOmaha$10K
- John GoertzOmaha$8K
- Andrea CardaPlattsmouth$7K
- Jordan ArensOmaha$7K
- Mandy JohnsonKearney$6K
- William GeisertLincoln$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.